Exhaled breath drug detection using differential mobility spectrometry

项目概要 该提案旨在扩展 NIH 正在积极研究的呼吸分析技术 授予 #6R42DA049655-02 并利用该技术进行快速 COVID-19 诊断。有一个迫切的需要 用于可快速执行的针对 COVID-19 的敏感且特定的诊断测试。差异迁移率 目前正在研究用于药物检测的光谱测定 (DMS) 呼吸分析技术可能会被采用 来填补这个空白。 在本补充材料中，我们将进行生物标志物发现工作，以确定呼出气分子 最适合用作 COVID-19 生物标志物的物种。一旦确定了目标物种， 将研究可在管理 COVID-19 测试的安全范式内实施的捕获。 我们还将启动与 FDA 的对话并制定 FDA 批准策略以加快部署 未来基于呼吸的 COVID-19 诊断仪器基于本项下正在研究的技术 行政补助的家长补助金。

Project Summary This proposal seeks to expand upon breath analysis technology that is being actively studied as the focus of NIH grant #6R42DA049655-02 and leverage this technology for rapid COVID-19 diagnostics. There is a dire need for sensitive and specific diagnostic tests for COVID-19 that can be performed quickly. The differential mobility spectrometry (DMS) breath analysis technology currently under investigation for drug detection may be adapted to fill this void. During this supplement we will perform a biomarker discovery effort to determine the exhaled breath molecular species most suitable for use as a COVID-19 biomarker. Once a target species has been identified, methods of capture that can be implemented within the safety paradigm governing COVID-19 testing will be investigated. We will also initiate conversation with the FDA and develop an FDA approval strategy to expedite the deployment of a future breath based COVID-19 diagnostic instrument based upon the technology being studied under this administrative supplement’s parent grant.